Kula Investments’s Myriad Genetics MYGN Stock Holding History

Kula Investments’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,577	Closed	-$197K	–	777
2022 Q4	$197K	Buy	+13,577	New	+$253K	0.06%	528

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Kula Investments's MYGN Position: Q1 2023 in Review

Kula Investments sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 13,577 shares — an estimated $197K sold.

Kula Investments first reported a position in MYGN in Q4 2022 and held it in 1 quarter. The position peaked at $197K in Q4 2022. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

Kula Investments reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
Kula Investments sold 13,577 Myriad Genetics shares in Q1 2023, an estimated $197K.
Kula Investments first reported a position in Myriad Genetics in Q4 2022 and held it in 1 quarter.
Kula Investments's Myriad Genetics position peaked at $197K in Q4 2022.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.